86. 肺動脈性肺高血圧症 Pulmonary arterial hypertension Clinical trials / Disease details


臨床試験数 : 1,205 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

  
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-001193-28-AT
(EUCTR)
08/11/200504/10/2005ARIES-320/321-E A Long-Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 or AMB-321 - 320/321-EARIES-320/321-E A Long-Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 or AMB-321 - 320/321-E Pulmonary Arterial HypertensionProduct Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Product Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Product Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Product Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Myogen, IncNULLNot RecruitingFemale: yes
Male: yes
372Austria
2EUCTR2005-000812-29-AT
(EUCTR)
08/11/200504/10/2005ARIES-1 Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension” - ARIES-1ARIES-1 Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension” - ARIES-1 Pulmonary Arterial HypertensionProduct Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Product Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Product Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Myogen, IncNULLNot RecruitingFemale: yes
Male: yes
186Phase 3Hungary;Belgium;Spain;Austria;Germany;Italy
3EUCTR2005-000812-29-DE
(EUCTR)
07/11/200502/03/2007ARIES-1 Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension” - ARIES-1ARIES-1 Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension” - ARIES-1 Pulmonary Arterial HypertensionProduct Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Product Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Product Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Myogen, IncNULLNot RecruitingFemale: yes
Male: yes
186Phase 3Hungary;Germany;Belgium;Spain;Italy
4EUCTR2005-000812-29-ES
(EUCTR)
21/10/200519/09/2005ARIES-1 Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension” - ARIES-1ARIES-1 Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension” - ARIES-1 Pulmonary Arterial HypertensionProduct Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Product Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Product Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Myogen, IncNULLNot RecruitingFemale: yes
Male: yes
186Phase 3Hungary;Belgium;Spain;Austria;Germany;Italy
5EUCTR2005-000812-29-HU
(EUCTR)
21/09/200511/08/2005Ambrisentan in PAH - A Phase III, Randomised, Double- Blind, Placebo- Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension - ARIES-1 Ambrisentan in PAH - A Phase III, Randomised, Double- Blind, Placebo- Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension - ARIES-1 Pulmonary Arterial Hypertension
MedDRA version: 7.0;Level: low;Classification code 10037400
Product Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Product Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Product Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Myogen, Inc.NULLNot RecruitingFemale: yes
Male: yes
186Phase 3Hungary;Belgium;Spain;Austria;Germany;Italy
6EUCTR2005-000812-29-BE
(EUCTR)
16/09/200508/02/2006ARIES-1 Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension” - ARIES-1ARIES-1 Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension” - ARIES-1 Pulmonary Arterial HypertensionProduct Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Product Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Product Name: Ambrisentan
Product Code: BSF 208075
INN or Proposed INN: Ambrisentan
Myogen, IncNULLNot RecruitingFemale: yes
Male: yes
186Phase 3Hungary;Germany;Belgium;Spain;Italy
7EUCTR2005-001564-31-BE
(EUCTR)
16/08/200515/12/2005A phase 2, Open-label, Multicenter Study Evaluating Ambrisentan in Subjects with Pulmonary Arterial Hypertension Who Have Previously Discontinued Endothelin Receptor Antagonist Therapy Due to Serum Aminotransferase Abnormalities - NAA phase 2, Open-label, Multicenter Study Evaluating Ambrisentan in Subjects with Pulmonary Arterial Hypertension Who Have Previously Discontinued Endothelin Receptor Antagonist Therapy Due to Serum Aminotransferase Abnormalities - NA Pulmonary Arterial Hypertension
MedDRA version: 7.0;Level: low;Classification code 10037400
Product Name: Ambrisentan
Product Code: BSF 208075 or LU 208075
INN or Proposed INN: Ambrisentan
INN or Proposed INN: Ambrisentan
INN or Proposed INN: Ambrisentan
Myogen Inc.NULLNot RecruitingFemale: yes
Male: yes
30Phase 2Belgium;Germany
8NCT00046319
(ClinicalTrials.gov)
September 200226/9/2002Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial HypertensionA Phase II, Randomized, Double-Blind, Dose-Controlled, Dose-Ranging, Multicenter Study of BSF 208075 Evaluating Exercise Capacity in Patients With Moderate to Severe Pulmonary Arterial HypertensionPulmonary HypertensionDrug: BSF 208075Gilead SciencesNULLCompleted18 YearsN/ABoth60Phase 2United States;Australia;Belgium;France;Germany;Italy